On September 9, 2008, Petrovax Group launched a new manufacturing facility for innovative local Grippol plus flu vaccine. The facility is unrivalled in Russia. Petrovax Group has completed a
The facility’s rated capacity is 80 m doses of various immunobiologicals a year; if necessary, their output may be quickly upscaled. The facility will also manufacture improved Grippol vaccine analogues, such as Grippol plus and Grippol TS, as well as a number of other pharmaceutical products.
This product is unique because of being the only local vaccine that is
It is worth noting that Petrovax Group targets not only domestic but also foreign market. In near future, the facility products will be exported to CIS countries, Slovakia, and Croatia.
The facility launch in Moscow region is a vivid example of the implementation of Petrovax Group’s innovative strategy based on the development, production, and practical application of original pharmaceuticals driven by fundamental research.